Revenue Growth Across the Business
TMO grew total revenue to $11.0B in Q1 FY2026, up $641M or 6.2% year-over-year from $10.36B, demonstrating continued demand for its life sciences products and services despite a challenging macro environment.
THERMO FISHER SCIENTIFIC INC. is expected to release its Q2 2026 10-Q filing in the upcoming earnings season. Last quarter: Thermo Fisher Scientific delivered solid Q1 FY2026 results with revenue of $11.0B (+6.2% YoY), net income of $1.65B (+9.6% YoY), and a significant jump in operating cash flow (+64.9% YoY), though long-term debt surged 26.4% reflecting major acquisition activity.
Drawn from management commentary in the Q1 2026 10-Q:
TMO grew total revenue to $11.0B in Q1 FY2026, up $641M or 6.2% year-over-year from $10.36B, demonstrating continued demand for its life sciences products and services despite a challenging macro environment.
Operating income rose 8.6% to $1.86B, outpacing revenue growth and expanding operating margin modestly to 16.93% from 16.56% in the prior year period, indicating improving cost efficiency and operating leverage.
Operating cash flow surged 64.9% year-over-year to $1.19B from $723M, a significant improvement that signals stronger working capital management and earnings quality in Q1 FY2026.
Revenue
$11.01B
++6.18% YoY
EPS (Basic)
$4.44
++11.28% YoY
Operating Income
$1.86B
++8.57% YoY
Add TMO to your watchlist to get the AI analysis in your inbox within minutes of the 10-Q filing.